Blog
RSS FeedPosted by Michael Wonder on 27 Mar 2023
Kite's Yescarta (axicabtagene ciloleucel) first CAR T-cell therapy to receive Health Canada authorisation for use in second-line large B-cell lymphoma
23 March 2023 - Landmark ZUMA-7 study demonstrated patients on Yescarta were 2.5 times more likely to be alive at ...
Posted by Michael Wonder on 27 Mar 2023
Health Canada authorises Imbruvica (ibrutinib) in a fixed duration combination with venetoclax for adult patients with previously untreated chronic lymphocytic leukaemia
23 March 2023 - All oral, once daily, fixed duration combination regimen authorised for first-line treatment of CLL. ...
Posted by Michael Wonder on 27 Mar 2023
Columvi (glofitamab for injection) receives Health Canada authorisation with conditions for adult patients with relapsed or refractory diffuse large B-cell lymphoma
25 March 2023 - Authorization is based on results from the Phase 1/2 NP30179 study, which demonstrated Columvi induced durable response ...
Posted by Michael Wonder on 27 Mar 2023
Health Canada approves first treatment option for generalised pustular psoriasis flares in adults
24 March 2023 - In the EFFISAYIL-1 trial, over half of the Spevigo (spesolimab) treated patients were free of pustules, ...
Posted by Michael Wonder on 23 Mar 2023
Investments to support access to drugs for rare diseases
22 March 2023 - Today, the Government announced a total investment of up to $1.5 billion over three years in ...
Posted by Michael Wonder on 23 Mar 2023
Government of Canada improves access to affordable and effective drugs for rare diseases
22 March 2023 - Today, the Honourable Jean-Yves Duclos, Minister of Health, announced measures in support of the first-ever National Strategy ...
Posted by Michael Wonder on 20 Mar 2023
Resignations at Canada’s drug pricing panel raise independence questions
14 March 2023 - A member of Canada’s drug pricing regulator has resigned, stating the federal government has undermined the ...
Posted by Michael Wonder on 19 Mar 2023
Lower drug prices are a good thing. Canada’s approach to achieving them was not.
17 March 2023 - Over the past six years, the Patented Medicine Prices Review Board – Canada’s federal drug-price regulating agency ...
Posted by Michael Wonder on 10 Mar 2023
Alberta’s import of children’s medication to cost taxpayers $80 million
9 March 2023 - Alberta taxpayers are on the hook for $80 million, after Health Minister Jason Copping finally revealed ...
Posted by Michael Wonder on 09 Mar 2023
Samsung Bioepis launches Lucentis biosimilar in Canada, Germany
5 March 2023 - According to industry sources on Sunday, SB11 was introduced to the Canadian market last Wednesday through its ...
Posted by Michael Wonder on 09 Mar 2023
CADTH recommends reimbursement for BioCryst’s Orladeyo (berotralstat) for the routine prevention of attacks in hereditary angioedema patients in Canada
8 March 2023 - BioCryst Pharmaceuticals today announced that the CADTH Canadian Drug Expert Committee has issued a positive recommendation ...
Posted by Michael Wonder on 08 Mar 2023
Jazz Pharmaceuticals secures eight additional provincial reimbursements for Vyxeos for treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes
8 March 2023 - Jazz Pharmaceuticals announced today that Vyxeos (daunorubicin and cytarabine liposome for injection) is now included on eight ...
Posted by Michael Wonder on 03 Mar 2023
Health minister disputes claim he sided with big pharma, interfered with drug price consultations
1 March 2023 - Review board 'will never be subjected to political interference,' Duclos said. ...
Posted by Michael Wonder on 01 Mar 2023
The drug prices review board was once a solution. It’s now a problem.
1 March 2023 - Anti-drug company activists are repeating ill-informed myths about controlling drug prices in Canada. ...
Posted by Michael Wonder on 24 Feb 2023
Member of Canada’s drug pricing regulator quits over ‘lack of support’ for medicine cost reforms
23 February 2023 - A member of the Patented Medicine Prices Review Board, Canada’s drug pricing regulator, has resigned over ...